RecruitingNCT03014609
Cardiovascular Risk and Chronic Obstructive Pulmonary Disease
Cardiovascular Risk and Chronic Obstructive Pulmonary Disease (COPD)
Sponsor
University Hospital, Grenoble
Enrollment
150 participants
Start Date
Jan 9, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
The principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (CVR) in COPD patients, using multivariate analysis.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria15
- For patients with stable COPD:
- Men or women aged 18 to 85
- FEV1/FVC \< 70% or proven BPCO
- Patients who have given their free and informed consent in writing
- For patients with decompensated COPD:
- Men or women aged 18 to 85
- FEV1/FVC \< 70% or proven BPCO
- At the time of acute respiratory failure (ARF), when admitted to hospital:
- Respiratory rate \> 25 cycles per minute
- PaCO2 \> 45 mmHg
- blood pH \< 7.35
- When included in the study:
- pH \> 7.33 at the end of ARF, 2 days in a row, or 3 to 7 days post-D1 decompensation (admission to the hospital)
- Fever \< 38.5°C
- Patients who have given their free and informed consent in writing
Exclusion Criteria9
- Obvious evolving infection or CRP \> 100 mg/L
- Cardiac decompensation considered the main cause of decompensation or chronic heart failure with LVEF \< 45%
- Evolving neoplasia
- On antioxidants: N-acetyl-cysteine, selenium, vit. C, vit. E
- Pregnant or nursing women
- Patients under tutorship or curatorship
- Patients participating in a drug clinical research study
- Patients not affiliated to the French social security system (or equivalent)
- Patients deprived of liberty or hospitalized without consent.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03014609
Related Trials
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
NCT070739506 locations
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
NCT0706982912 locations
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
NCT066032467 locations
Different Inspiratory Muscle Trainings in Patients With COPD
NCT074066591 location
Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
NCT034506031 location